logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Seeks Addl Information To Complete Review Of HyQ BLA - Quick Facts

Baxter International Inc. (BAX) and Halozyme Therapeutics Inc. (HALO) announced that the U.S. Food and Drug Administration is requesting additional information to complete its review of the HyQ Biologics License Application or BLA.

Baxter and Halozyme said that they will work closely together to develop studies to provide additional data to address concerns raised by the FDA related to the long-term chronic use of HyQ. The companies now expect to participate in a meeting of the FDA's Blood Products Advisory Committee concerning the agency's request for additional data.

The companies expect these requests to require additional time to complete and to delay the companies' anticipated regulatory review and approval timeline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
British integrated oil and gas major BP Plc. (BP.L, BP_UN.TO, BP) Tuesday announced a narrower replacement cost loss for the second quarter from the prior year. Revenues were hit by lower oil prices. The company said the results draws a line under Deepwater Horizon liabilities, despite strong operations... Telecommunications giant Verizon Communications, Inc. on Tuesday an 83 percent plunge in profit for the second quarter from last year on lower revenues and higher expenses. However, adjusted earnings per share for the quarter topped analysts' expectations, while revenues missed their estimates. Telecommunications giant Verizon Communications, Inc. on Tuesday an 83 percent plunge in profit for the second quarter from last year on lower revenues and higher expenses. However, adjusted earnings per share for the quarter topped analysts' expectations, while revenues missed their estimates.
comments powered by Disqus
Follow RTT